Praveen Tipirneni, Morphic Therapeutic CEO
Lilly discloses its first biotech acquisition of the year, buying Morphic for $3.2B
Eli Lilly said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
